You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarvedilol
Accession NumberDB01136  (APRD00091)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionCarvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.
Structure
Thumb
Synonyms
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
Carvedilol
Carvedilolum
SKF 105517
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-carvedilolTablet12.5 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet25 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet3.125 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet6.25 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Ava-carvedilolTablet6.25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet12.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet3.125 mgOralAvanstra Inc2011-10-112014-08-21Canada
CarvedilolTablet3.125 mgOralMeliapharm Inc2010-06-012014-06-25Canada
CarvedilolTablet25 mgOralSivem Pharmaceuticals Ulc2004-04-06Not applicableCanada
CarvedilolTablet12.5 mgOralPro Doc Limitee2009-06-12Not applicableCanada
CarvedilolTablet12.5 mgOralSanis Health Inc2011-06-10Not applicableCanada
CarvedilolTablet6.25 mgOralMeliapharm Inc2010-05-172014-06-25Canada
CarvedilolTablet25.0 mgOralPro Doc Limitee2009-06-12Not applicableCanada
CarvedilolTablet3.125 mgOralSivem Pharmaceuticals Ulc2004-04-06Not applicableCanada
CarvedilolTablet25 mgOralSanis Health Inc2011-06-10Not applicableCanada
CarvedilolTablet3.125 mgOralPro Doc Limitee2009-06-12Not applicableCanada
CarvedilolTablet12.5 mgOralMeliapharm Inc2010-05-172014-06-25Canada
CarvedilolTablet3.125 mgOralSanis Health Inc2011-06-10Not applicableCanada
CarvedilolTablet6.25 mgOralSivem Pharmaceuticals Ulc2004-04-06Not applicableCanada
CarvedilolTablet6.25 mgOralPro Doc Limitee2009-06-12Not applicableCanada
CarvedilolTablet6.25 mgOralSanis Health Inc2011-06-10Not applicableCanada
CarvedilolTablet12.5 mgOralSivem Pharmaceuticals Ulc2004-04-06Not applicableCanada
CoregTablet, film coated6.25 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
CoregTablet, film coated12.5 mg/1OralGlaxo Smith Kline Llc1997-06-03Not applicableUs
CoregTablet, film coated3.125 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
CoregTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2003-06-20Not applicableUs
CoregTablet, film coated25 mg/1OralGlaxo Smith Kline Llc1997-06-03Not applicableUs
CoregTablet, film coated25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
CoregTablet, film coated12.5 mg/1OralPhysicians Total Care, Inc.2002-05-23Not applicableUs
CoregTablet, film coated3.125 mg/1OralGlaxo Smith Kline Llc1997-06-03Not applicableUs
CoregTablet, film coated12.5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
CoregTablet, film coated3.125 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
CoregTablet, film coated6.25 mg/1OralGlaxo Smith Kline Llc1997-06-03Not applicableUs
Coreg (carvedilol) Tablets, 12.5mgTablet12.5 mgOralGlaxosmithkline Inc1996-10-172006-10-11Canada
Coreg (carvedilol) Tablets, 25mgTablet25 mgOralGlaxosmithkline Inc1996-10-172006-10-11Canada
Coreg (carvedilol) Tablets, 3.125 mgTablet3.125 mgOralGlaxosmithkline Inc1996-10-172006-10-11Canada
Coreg (carvedilol) Tablets, 6.25mgTablet6.25 mgOralGlaxosmithkline Inc1996-10-172006-10-11Canada
Coreg 12.5mgTablet12.5 mgOralHoffmann La Roche Limited2000-04-192001-07-18Canada
Coreg 25mgTablet25 mgOralHoffmann La Roche Limited2000-03-222001-07-18Canada
Coreg 3.125mgTablet3.125 mgOralHoffmann La Roche Limited2000-05-292001-07-18Canada
Coreg 6.25mgTablet6.25 mgOralHoffmann La Roche Limited2000-12-062001-07-18Canada
Coreg CRCapsule, extended release10 mg/1OralGlaxo Smith Kline Llc2007-02-09Not applicableUs
Coreg CRCapsule, extended release10 mg/1OralCarilion Materials Management2007-02-09Not applicableUs
Coreg CRCapsule, extended release20 mg/1OralGlaxo Smith Kline Llc2007-02-06Not applicableUs
Coreg CRCapsule, extended release20 mg/1OralCarilion Materials Management2007-02-06Not applicableUs
Coreg CRCapsule, extended release40 mg/1OralGlaxo Smith Kline Llc2007-02-14Not applicableUs
Coreg CRCapsule, extended release40 mg/1OralCarilion Materials Management2007-02-14Not applicableUs
Coreg CRCapsule, extended release80 mg/1OralGlaxo Smith Kline Llc2007-02-20Not applicableUs
Coreg CRCapsule, extended release80 mg/1OralCarilion Materials Management2007-02-20Not applicableUs
Coregcr CRCapsule, extended release20 mg/1OralPhysicians Total Care, Inc.2008-08-25Not applicableUs
Coregcr CRCapsule, extended release80 mg/1OralPhysicians Total Care, Inc.2007-05-23Not applicableUs
Coregcr CRCapsule, extended release40 mg/1OralPhysicians Total Care, Inc.2008-05-09Not applicableUs
Coregcr CRCapsule, extended release10 mg/1OralPhysicians Total Care, Inc.2009-04-15Not applicableUs
Dilatrend - Tab 25mgTablet25 mgOralHoffmann La Roche LimitedNot applicableNot applicableCanada
Dilatrend - Tab 50mgTablet50 mgOralHoffmann La Roche LimitedNot applicableNot applicableCanada
Dom-carvedilolTablet25 mgOralDominion Pharmacal2004-03-01Not applicableCanada
Dom-carvedilolTablet3.125 mgOralDominion Pharmacal2004-03-01Not applicableCanada
Dom-carvedilolTablet6.25 mgOralDominion Pharmacal2004-03-01Not applicableCanada
Dom-carvedilolTablet12.5 mgOralDominion Pharmacal2004-03-01Not applicableCanada
Jamp-carvedilolTablet6.25 mgOralJamp Pharma Corporation2011-06-17Not applicableCanada
Jamp-carvedilolTablet12.5 mgOralJamp Pharma Corporation2011-06-17Not applicableCanada
Jamp-carvedilolTablet25 mgOralJamp Pharma Corporation2011-06-17Not applicableCanada
Jamp-carvedilolTablet3.125 mgOralJamp Pharma Corporation2011-06-17Not applicableCanada
Mylan-carvedilolTablet12.5 mgOralMylan Pharmaceuticals Ulc2010-03-30Not applicableCanada
Mylan-carvedilolTablet25 mgOralMylan Pharmaceuticals Ulc2010-03-30Not applicableCanada
Mylan-carvedilolTablet3.125 mgOralMylan Pharmaceuticals Ulc2010-03-30Not applicableCanada
Mylan-carvedilolTablet6.25 mgOralMylan Pharmaceuticals Ulc2010-03-30Not applicableCanada
Novo-carvedilol TabletsTablet12.5 mgOralNovopharm Limited2003-11-282015-10-26Canada
Novo-carvedilol TabletsTablet25 mgOralNovopharm Limited2003-11-282015-10-26Canada
Novo-carvedilol TabletsTablet3.125 mgOralNovopharm Limited2003-12-022015-10-26Canada
Novo-carvedilol TabletsTablet6.25 mgOralNovopharm Limited2003-11-282015-10-26Canada
Ntp-carvedilolTablet12.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-carvedilolTablet25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-carvedilolTablet3.125 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-carvedilolTablet6.25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-carvedilolTablet25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-carvedilolTablet3.125 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-carvedilolTablet6.25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-carvedilolTablet12.5 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-carvedilolTablet25 mgOralPharmascience Inc2003-08-04Not applicableCanada
PMS-carvedilolTablet3.125 mgOralPharmascience Inc2003-08-04Not applicableCanada
PMS-carvedilolTablet6.25 mgOralPharmascience Inc2003-08-04Not applicableCanada
PMS-carvedilolTablet12.5 mgOralPharmascience Inc2003-08-04Not applicableCanada
Ran-carvedilolTablet12.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-22Not applicableCanada
Ran-carvedilolTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-22Not applicableCanada
Ran-carvedilolTablet3.125 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-22Not applicableCanada
Ran-carvedilolTablet6.25 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-22Not applicableCanada
Ratio-carvedilolTablet25 mgOralTeva Canada Limited2004-05-04Not applicableCanada
Ratio-carvedilolTablet3.125 mgOralTeva Canada Limited2004-05-04Not applicableCanada
Ratio-carvedilolTablet6.25 mgOralTeva Canada Limited2004-05-04Not applicableCanada
Ratio-carvedilolTablet12.5 mgOralTeva Canada Limited2004-05-04Not applicableCanada
Zym-carvedilolTablet6.25 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Zym-carvedilolTablet12.5 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Zym-carvedilolTablet25 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Zym-carvedilolTablet3.125 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-carvedilolTablet6.25 mgOralApotex Inc2003-08-06Not applicableCanada
Apo-carvedilolTablet12.5 mgOralApotex Inc2003-08-06Not applicableCanada
Apo-carvedilolTablet25 mgOralApotex Inc2003-08-06Not applicableCanada
Apo-carvedilolTablet3.125 mgOralApotex Inc2003-08-06Not applicableCanada
CarvedilolTablet, film coated25 mg/1OralPreferred Pharmaceuticals, Inc2016-11-15Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAv Kare, Inc.2014-01-142016-10-13Us
CarvedilolTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-06Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-04-112016-04-05Us
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAurolife Pharma LLC2009-03-23Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralClinical Solutions Wholesale, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralProficient Rx LP2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2013-12-11Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAurobindo Pharma Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralMylan Institutional Inc.2007-09-14Not applicableUs
CarvedilolTablet, film coated25 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralCardinal Health2010-06-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-052016-10-26Us
CarvedilolTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2016-09-23Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralUnit Dose Services2010-06-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMylan Pharmaceuticals Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralUnit Dose Services2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralMajor Pharmaceuticals2012-11-14Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2008-07-03Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralHikma Pharmaceutical2007-10-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAvera Mc Kennan Hospital2015-10-19Not applicableUs
CarvedilolTablet, film coated25 mg/1Oralbryant ranch prepack2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-09-06Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2014-03-19Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralPreferred Pharmaceuticals, Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralApotex Corp.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralH.J. Harkins Company, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralClinical Solutions Wholesale, Llc2010-06-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralProficient Rx LP2007-09-05Not applicableUs
CarvedilolTablet25 mg/1OralCipla USA Inc.2007-09-05Not applicableUs
CarvedilolTablet12.5 mg/1OralRed Pharm Drug Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2012-08-29Not applicableUs
CarvedilolTablet, film coated25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralClinical Solutions Wholesale2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralPreferred Pharmaceuticals,Inc.2012-06-04Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-04-28Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralPd Rx Pharmaceuticals, Inc.2009-03-23Not applicableUs
CarvedilolTablet6.25 mg/1OralMajor Pharmaceuticals2010-06-18Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-05-102016-10-13Us
CarvedilolTablet, film coated6.25 mg/1OralLucid Pharma Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralSun Pharmaceutical Industries, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralSt Marys Medical Park Pharmacy2013-04-25Not applicableUs
CarvedilolTablet, film coated25 mg/1OralSolco Healthcare US LLC2010-06-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralCadila Healthcare Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralSandoz Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralCardinal Health2011-02-18Not applicableUs
CarvedilolTablet, film coated25 mg/1OralMc Kesson Contract Packaging2011-09-21Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
CarvedilolTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralDr. Reddy's Laboratories Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralBAYSHORE PHARMACEUTICALS LLC2016-10-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-03-052016-04-05Us
CarvedilolTablet, film coated3.125 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCardinal Health2010-06-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralA S Medication Solutions2007-09-06Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAv Kare, Inc.2014-01-142016-10-13Us
CarvedilolTablet12.5 mg/1OralMajor Pharmaceuticals2010-06-18Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-04-152016-04-05Us
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2013-07-082016-04-05Us
CarvedilolTablet, film coated25 mg/1OralAurolife Pharma LLC2009-03-23Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralClinical Solutions Wholesale, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralProficient Rx LP2007-09-05Not applicableUs
CarvedilolTablet3.125 mg/1OralCipla USA Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAurobindo Pharma Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralMylan Institutional Inc.2007-09-14Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralGlenmark Pharmaceuticals Inc., Usa2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralClinical Solutions Wholesale2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralPreferred Pharmaceuticals,Inc.2014-12-03Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2015-04-162016-11-15Us
CarvedilolTablet6.25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralDr. Reddy's Laboratories Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralBAYSHORE PHARMACEUTICALS LLC2016-10-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralUnit Dose Services2010-06-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralMylan Pharmaceuticals Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/301OralNorthwind Pharmaceuticals2014-05-16Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCardinal Health2008-07-03Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralHikma Pharmaceutical2007-10-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralSolco Healthcare US LLC2010-06-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCadila Healthcare Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralSandoz Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCardinal Health2011-02-18Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMc Kesson Contract Packaging2011-09-20Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralLucid Pharma Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralClinical Solutions Wholesale, Llc2010-06-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1Oralbryant ranch prepack2009-03-23Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-09-06Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAmerican Health Packaging2008-07-032016-05-31Us
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-01-08Not applicableUs
CarvedilolTablet, film coated25 mg/1OralLegacy Pharmaceutical Packaging2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralApotex Corp.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAvera Mc Kennan Hospital2015-11-04Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralPhysicians Total Care, Inc.2007-11-09Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2016-06-03Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMajor Pharmaceuticals2012-11-14Not applicableUs
CarvedilolTablet12.5 mg/1OralREMEDYREPACK INC.2012-01-172016-10-25Us
CarvedilolTablet, film coated12.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-02-092016-04-05Us
CarvedilolTablet, film coated3.125 mg/1OralAurolife Pharma LLC2009-03-23Not applicableUs
CarvedilolTablet, film coated25 mg/1OralSun Pharmaceutical Industries, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralSt Marys Medical Park Pharmacy2013-04-25Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralUnit Dose Services2009-03-23Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAurobindo Pharma Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralUnit Dose Services2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAmerican Health Packaging2008-07-032015-11-30Us
CarvedilolTablet, film coated25 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
CarvedilolTablet3.125 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralA S Medication Solutions2010-06-01Not applicableUs
CarvedilolTablet25 mg/1OralCardinal Health2010-06-04Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2016-11-10Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralRebel Distributors Corp2009-03-23Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralClinical Solutions Wholesale2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-27Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralCardinal Health2010-06-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-06Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAv Kare, Inc.2014-01-142016-10-13Us
CarvedilolTablet25 mg/1OralMajor Pharmaceuticals2010-06-04Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-03-052016-10-13Us
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2013-03-112016-04-05Us
CarvedilolTablet, film coated25 mg/1OralClinical Solutions Wholesale, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralProficient Rx LP2007-09-05Not applicableUs
CarvedilolTablet6.25 mg/1OralCipla USA Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMed Vantx, Inc.2011-09-13Not applicableUs
CarvedilolTablet, film coated25 mg/1OralMylan Institutional Inc.2007-09-14Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralSandoz Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
CarvedilolTablet, film coated25 mg/1OralCardinal Health2011-02-18Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2015-04-28Not applicableUs
CarvedilolTablet12.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralDr. Reddy's Laboratories Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralBAYSHORE PHARMACEUTICALS LLC2016-10-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralMylan Pharmaceuticals Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-09Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralSun Pharmaceutical Industries, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralHikma Pharmaceutical2007-10-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralSolco Healthcare US LLC2010-06-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralCadila Healthcare Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-05-142016-10-13Us
CarvedilolTablet, film coated25 mg/1OralLucid Pharma Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralClinical Solutions Wholesale, Llc2010-06-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1Oralbryant ranch prepack2009-03-23Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-09-06Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAmerican Health Packaging2008-07-032016-01-31Us
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-01-21Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralPreferred Pharmaceuticals, Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralApotex Corp.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAvera Mc Kennan Hospital2015-11-10Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralPhysicians Total Care, Inc.2007-09-24Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-06-03Not applicableUs
CarvedilolTablet, film coated25 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralUnit Dose Services2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralMajor Pharmaceuticals2012-11-14Not applicableUs
CarvedilolTablet3.125 mg/1OralREMEDYREPACK INC.2011-08-022016-10-13Us
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-12-112016-04-05Us
CarvedilolTablet, film coated6.25 mg/1OralAurolife Pharma LLC2009-03-23Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralClinical Solutions Wholesale, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralSt Marys Medical Park Pharmacy2013-04-25Not applicableUs
CarvedilolTablet, film coated25 mg/1OralUnit Dose Services2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAurobindo Pharma Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMylan Institutional Inc.2007-09-14Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralZydus Pharmaceuticals (USA) Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralA S Medication Solutions2007-09-052016-10-21Us
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2010-06-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralPreferred Pharmaceuticals, Inc2016-11-15Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAv Kare, Inc.2014-01-142016-10-13Us
CarvedilolTablet, film coated12.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet12.5 mg/1OralCipla USA Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralMed Vantx, Inc.2007-09-06Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2012-07-19Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralClinical Solutions Wholesale2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralPreferred Pharmaceuticals, Inc.2012-10-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarvedilolTablet, film coated25 mg/1OralA S Medication Solutions2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralDIRECT RX2014-01-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
CarvedilolTablet3.125 mg/1OralMajor Pharmaceuticals2010-06-07Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2013-03-012016-10-13Us
CarvedilolTablet, film coated3.125 mg/1OralLucid Pharma Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralREMEDYREPACK INC.2013-03-112016-04-05Us
CarvedilolTablet, film coated3.125 mg/1OralClinical Solutions Wholesale, Llc2010-06-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralProficient Rx LP2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralSt Marys Medical Park Pharmacy2013-04-25Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralSolco Healthcare US LLC2010-06-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralCadila Healthcare Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralSandoz Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2011-02-18Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralMc Kesson Contract Packaging2011-09-21Not applicableUs
CarvedilolTablet, film coated25 mg/1OralREMEDYREPACK INC.2015-12-16Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralA S Medication Solutions2010-06-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralDr. Reddy's Laboratories Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralBAYSHORE PHARMACEUTICALS LLC2016-10-01Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2013-03-25Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralSun Pharmaceutical Industries, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralMajor Pharmaceuticals2012-11-14Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2013-03-292016-04-05Us
CarvedilolTablet12.5 mg/1OralH.J. Harkins Company, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralHikma Pharmaceutical2007-10-01Not applicableUs
CarvedilolTablet, film coated3.125 mg/1Oralbryant ranch prepack2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-09-06Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralAmerican Health Packaging2008-07-032016-02-29Us
CarvedilolTablet, film coated3.125 mg/1OralREMEDYREPACK INC.2013-04-09Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralPreferred Pharmaceuticals, Inc2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralApotex Corp.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralAvera Mc Kennan Hospital2015-11-11Not applicableUs
CarvedilolTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralPhysicians Total Care, Inc.2009-08-12Not applicableUs
CarvedilolTablet, film coated12.5 mg/1OralREMEDYREPACK INC.2016-06-15Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralUnit Dose Services2007-09-05Not applicableUs
CarvedilolTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
COREGCRNot Available
Brand mixtures
NameLabellerIngredients
Hypertenevide-12.5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Carvedilol phosphate
ThumbNot applicableDBSALT001201
Categories
UNII0K47UL67F2
CAS number72956-09-3
WeightAverage: 406.4742
Monoisotopic: 406.18925733
Chemical FormulaC24H26N2O4
InChI KeyOGHNVEJMJSYVRP-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
SMILES
COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
Pharmacology
IndicationFor the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.
Structured Indications
PharmacodynamicsCarvedilol is a nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in which nonselective b-adrenoreceptor blocking activity is present in the S(-) enantiomer and a-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's b-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise-and/or isoproterenol-induced tachycardia and (3) reduces reflex orthostatic tachycardia.
Mechanism of actionCarvedilol is a racemic mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S(-) enantiomer and alpha-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol's beta-adrenergic receptor blocking ability decreases the heart rate, myocardial contractility, and myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance via its alpha adrenergic receptor blocking properties. Carvedilol and its metabolite BM-910228 (a less potent beta blocker, but more potent antioxidant) have been shown to restore the inotropic responsiveness to Ca2+ in OH- free radical-treated myocardium. Carvedilol and its metabolites also prevent OH- radical-induced decrease in sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites may be beneficial in chronic heart failure by preventing free radical damage.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
NADH dehydrogenase [ubiquinone] 1 subunit C2Proteinunknown
inhibitor
HumanO95298 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Vascular endothelial growth factor AProteinunknown
other
HumanP15692 details
Natriuretic peptides BProteinunknown
other
HumanP16860 details
Gap junction alpha-1 proteinProteinunknown
other
HumanP17302 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Vascular cell adhesion protein 1Proteinunknown
inhibitor
HumanP19320 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
E-selectinProteinunknown
inhibitor
HumanP16581 details
Hypoxia-inducible factor 1-alphaProteinunknown
modulator
HumanQ16665 details
Related Articles
AbsorptionCarvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
Volume of distribution
  • 115 L
Protein binding98%
Metabolism

Hepatic. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. Demethylation and hydroxylation at the phenol ring produce three active metabolites with b-receptor blocking activity. The 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for b-blockade.

SubstrateEnzymesProduct
Carvedilol
8-HydroxycarvedilolDetails
Carvedilol
4'-HydroxycarvedilolDetails
Carvedilol
5'-HydroxycarvedilolDetails
Carvedilol
O-DesmethylcarvedilolDetails
Carvedilol
1-HydroxycarvedilolDetails
Carvedilol
Not Available
4'-hydroxyphenyl CarvedilolDetails
Route of eliminationCarvedilol is extensively metabolized. Less than 2% of the dose was excreted unchanged in the urine. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces.
Half life7-10 hours
Clearance
  • 500-700 mL/min
ToxicityNot expected to be toxic following ingestion.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carvedilol Action PathwayDrug actionSMP00367
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableC AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801252 Not AvailableA AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Carvedilol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Carvedilol.Experimental
AbirateroneThe serum concentration of Carvedilol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Carvedilol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Carvedilol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Carvedilol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideCarvedilol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Carvedilol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Acetylcholine.Approved
AcetyldigitoxinCarvedilol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Carvedilol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Carvedilol.Approved
AdrafinilCarvedilol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Carvedilol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Carvedilol.Experimental
AlfentanilAlfentanil may increase the bradycardic activities of Carvedilol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Carvedilol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Carvedilol is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Carvedilol.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Carvedilol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Carvedilol.Approved, Investigational
AmifostineCarvedilol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Carvedilol.Approved
AmiodaroneThe serum concentration of Carvedilol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazCarvedilol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Carvedilol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carvedilol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Carvedilol.Approved, Illicit
AmodiaquineThe metabolism of Carvedilol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Carvedilol is combined with Amphotericin B.Approved, Investigational
AmrinoneCarvedilol may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Carvedilol is combined with Amyl Nitrite.Approved
AnisodamineCarvedilol may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Carvedilol.Approved
AnvirzelCarvedilol may increase the bradycardic activities of Anvirzel.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Carvedilol.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Carvedilol.Approved
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Carvedilol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
AprepitantThe serum concentration of Carvedilol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineCarvedilol may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Arecoline.Experimental
ArformoterolCarvedilol may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Carvedilol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Carvedilol.Approved, Investigational
ArtemetherThe metabolism of Carvedilol can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Carvedilol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
AtomoxetineThe metabolism of Carvedilol can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Carvedilol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Carvedilol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Carvedilol.Approved
AzelnidipineCarvedilol may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Azilsartan medoxomil.Approved
AzimilideCarvedilol may increase the hypotensive activities of Azimilide.Investigational
AzithromycinThe metabolism of Carvedilol can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Carvedilol.Experimental
BarbitalBarbital may increase the hypotensive activities of Carvedilol.Illicit
BarnidipineCarvedilol may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Carvedilol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carvedilol.Approved
BenidipineCarvedilol may increase the hypotensive activities of Benidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Carvedilol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Carvedilol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Illicit
BepridilCarvedilol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantCarvedilol may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Carvedilol.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Carvedilol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Carvedilol.Investigational
BevantololBevantolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BexaroteneThe serum concentration of Carvedilol can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BitolterolCarvedilol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Carvedilol.Investigational
BoceprevirThe metabolism of Carvedilol can be decreased when combined with Boceprevir.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BortezomibThe metabolism of Carvedilol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Carvedilol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Carvedilol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.Approved
BretyliumBretylium may increase the bradycardic activities of Carvedilol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Carvedilol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Carvedilol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Carvedilol.Investigational
BucindololCarvedilol may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Carvedilol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Carvedilol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BupropionThe metabolism of Carvedilol can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Carvedilol.Approved
CabergolineCarvedilol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Carvedilol.Approved
CaiCarvedilol may increase the hypotensive activities of Cai.Investigational
CalfactantCarvedilol may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Carvedilol.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Carvedilol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Carvedilol.Experimental
CapecitabineThe serum concentration of Carvedilol can be increased when it is combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Carvedilol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Carvedilol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Carvedilol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Carvedilol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Carvedilol.Experimental
CelecoxibThe metabolism of Carvedilol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CeritinibCarvedilol may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Carvedilol.Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Carvedilol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carvedilol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Carvedilol.Approved, Vet Approved
ChlorpropamideCarvedilol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carvedilol.Approved
CholecalciferolThe serum concentration of Carvedilol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cilazapril.Approved
CilnidipineCarvedilol may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Carvedilol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Carvedilol can be decreased when combined with Cinacalcet.Approved
CinnarizineCarvedilol may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CirazolineCarvedilol may decrease the vasoconstricting activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Carvedilol.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Carvedilol.Approved
ClarithromycinThe metabolism of Carvedilol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Carvedilol can be decreased when combined with Clemastine.Approved
ClenbuterolCarvedilol may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Carvedilol.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Carvedilol.Approved, Investigational
ClomipramineThe metabolism of Carvedilol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Carvedilol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Carvedilol.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Carvedilol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Carvedilol.Approved
CobicistatThe serum concentration of Carvedilol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Carvedilol.Approved
CocaineThe metabolism of Carvedilol can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Carvedilol.Approved
ConivaptanThe serum concentration of Carvedilol can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Carvedilol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Carvedilol.Vet Approved
CrizotinibThe metabolism of Carvedilol can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Carvedilol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Carvedilol.Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Carvedilol.Approved
Cyproterone acetateThe serum concentration of Carvedilol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Carvedilol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol.Approved
DabrafenibThe serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Carvedilol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Carvedilol.Investigational
DarifenacinThe metabolism of Carvedilol can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineCarvedilol may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Carvedilol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Carvedilol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Carvedilol.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Carvedilol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Carvedilol.Approved
DeferasiroxThe serum concentration of Carvedilol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Carvedilol can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Carvedilol.Approved
DeserpidineCarvedilol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Desflurane.Approved
DesipramineThe metabolism of Carvedilol can be decreased when combined with Desipramine.Approved
DeslanosideCarvedilol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Carvedilol can be increased when it is combined with Desvenlafaxine.Approved
DetomidineCarvedilol may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Carvedilol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Carvedilol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Carvedilol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Carvedilol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Carvedilol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Carvedilol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Carvedilol.Approved
DigoxinDigoxin may increase the bradycardic activities of Carvedilol.Approved
DihydralazineCarvedilol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Carvedilol.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Carvedilol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Carvedilol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Carvedilol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Carvedilol.Approved
DisulfiramThe metabolism of Carvedilol can be decreased when combined with Disulfiram.Approved
DobutamineCarvedilol may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Carvedilol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Carvedilol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Carvedilol.Approved
DotarizineCarvedilol may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Carvedilol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Carvedilol.Approved, Investigational
DoxycyclineThe metabolism of Carvedilol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the bradycardic activities of Carvedilol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Carvedilol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
DuloxetineCarvedilol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Carvedilol.Investigational
E6201E6201 may decrease the antihypertensive activities of Carvedilol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Carvedilol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Carvedilol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Carvedilol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Carvedilol.Approved
EfavirenzThe serum concentration of Carvedilol can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineCarvedilol may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Carvedilol.Approved, Investigational
EliglustatThe metabolism of Carvedilol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Carvedilol.Approved, Vet Approved
EnalaprilatCarvedilol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide.Approved
EperisoneCarvedilol may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Nutraceutical, Withdrawn
EphedrineCarvedilol may decrease the vasoconstricting activities of Ephedrine.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Carvedilol is combined with EPIBATIDINE.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Carvedilol.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Carvedilol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Carvedilol.Approved
EpoprostenolCarvedilol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carvedilol.Approved
Ergoloid mesylateCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineCarvedilol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Carvedilol.Approved, Investigational
ErythromycinThe metabolism of Carvedilol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Carvedilol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Carvedilol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Carvedilol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Carvedilol.Approved
EtilefrineCarvedilol may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Carvedilol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
EtoperidoneThe serum concentration of Carvedilol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Carvedilol.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
EtravirineThe serum concentration of Carvedilol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Carvedilol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Carvedilol.Approved
exisulindexisulind may decrease the antihypertensive activities of Carvedilol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Carvedilol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Carvedilol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Carvedilol.Approved
FendilineCarvedilol may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Carvedilol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Carvedilol.Approved
FenoterolCarvedilol may decrease the vasoconstricting activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Carvedilol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Carvedilol.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Carvedilol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Carvedilol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Carvedilol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Carvedilol is combined with Fimasartan.Approved
FingolimodCarvedilol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carvedilol.Approved, Withdrawn
FloxuridineThe serum concentration of Carvedilol can be increased when it is combined with Floxuridine.Approved
FluconazoleThe serum concentration of Carvedilol can be increased when it is combined with Fluconazole.Approved
FlunarizineCarvedilol may increase the hypotensive activities of Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Carvedilol.Vet Approved
FluorouracilThe serum concentration of Carvedilol can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe metabolism of Carvedilol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Carvedilol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Carvedilol.Approved
FluvastatinThe serum concentration of Carvedilol can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Carvedilol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolCarvedilol may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Carvedilol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Carvedilol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carvedilol.Approved
FosphenytoinThe metabolism of Carvedilol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Carvedilol.Approved, Vet Approved
Fusidic AcidThe serum concentration of Carvedilol can be increased when it is combined with Fusidic Acid.Approved
GabapentinCarvedilol may increase the hypotensive activities of Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Carvedilol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Carvedilol.Approved
GallopamilCarvedilol may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Carvedilol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Carvedilol.Approved
GemfibrozilThe serum concentration of Carvedilol can be increased when it is combined with Gemfibrozil.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Carvedilol.Approved, Nutraceutical
GlibornurideCarvedilol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideCarvedilol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCarvedilol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCarvedilol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneCarvedilol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideCarvedilol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideCarvedilol may increase the hypoglycemic activities of Glyburide.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Carvedilol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Carvedilol.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Carvedilol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Carvedilol.Approved
GuanethidineCarvedilol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Carvedilol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Halothane.Approved, Vet Approved
HexamethoniumCarvedilol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Carvedilol.Approved
HexoprenalineCarvedilol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineHigenamine may decrease the antihypertensive activities of Carvedilol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Carvedilol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Carvedilol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Carvedilol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carvedilol.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Carvedilol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Carvedilol.Approved
HydroxychloroquineThe metabolism of Carvedilol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Carvedilol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Carvedilol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Carvedilol.Approved
IdelalisibThe serum concentration of Carvedilol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
ImatinibThe metabolism of Carvedilol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Carvedilol.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Carvedilol.Approved
IndalpineThe serum concentration of Carvedilol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carvedilol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Carvedilol.Withdrawn
IndinavirThe serum concentration of Carvedilol can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Carvedilol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Carvedilol.Withdrawn
IndoraminCarvedilol may increase the antihypertensive activities of Indoramin.Withdrawn
Insulin PorkCarvedilol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Carvedilol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Carvedilol.Withdrawn
IrbesartanThe serum concentration of Carvedilol can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Carvedilol.Approved, Investigational
IsavuconazoniumThe metabolism of Carvedilol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Carvedilol.Approved
IsoetarineCarvedilol may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Carvedilol.Approved, Withdrawn
IsoniazidThe metabolism of Carvedilol can be decreased when combined with Isoniazid.Approved
IsoprenalineCarvedilol may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carvedilol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carvedilol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Carvedilol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Carvedilol.Approved
ItraconazoleThe metabolism of Carvedilol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineCarvedilol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Carvedilol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Carvedilol.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Carvedilol.Experimental
KetanserinCarvedilol may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Carvedilol.Approved
KetoconazoleThe serum concentration of Carvedilol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Carvedilol.Approved
LabetalolLabetalol may increase the antihypertensive activities of Carvedilol.Approved
LacidipineCarvedilol may increase the hypotensive activities of Lacidipine.Approved
LacosamideCarvedilol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Carvedilol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Carvedilol.Approved, Investigational
LanreotideCarvedilol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Carvedilol.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Carvedilol.Approved
LeflunomideThe serum concentration of Carvedilol can be increased when it is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Carvedilol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Carvedilol.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Carvedilol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Levobupivacaine.Approved
LevodopaCarvedilol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Carvedilol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Carvedilol is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Carvedilol can be decreased when combined with Lidocaine.Approved, Vet Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Carvedilol.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Carvedilol.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carvedilol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Carvedilol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Carvedilol.Approved
LopinavirThe metabolism of Carvedilol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Carvedilol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Carvedilol.Approved
LosartanThe serum concentration of Carvedilol can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Carvedilol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Carvedilol.Approved
LucinactantCarvedilol may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Carvedilol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carvedilol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Carvedilol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
MacitentanCarvedilol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Carvedilol.Approved
Magnesium SulfateCarvedilol may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
MalathionMalathion may increase the bradycardic activities of Carvedilol.Approved, Investigational
ManidipineCarvedilol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carvedilol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Carvedilol.Approved
MebanazineMebanazine may increase the hypotensive activities of Carvedilol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carvedilol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
MedetomidineCarvedilol may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Carvedilol.Approved
MefloquineMefloquine may increase the bradycardic activities of Carvedilol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Carvedilol.Approved, Investigational
MephentermineCarvedilol may decrease the vasoconstricting activities of Mephentermine.Approved
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Carvedilol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Carvedilol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Carvedilol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Carvedilol.Withdrawn
MetaraminolCarvedilol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Methacholine.Approved
MethadoneThe metabolism of Carvedilol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Carvedilol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Carvedilol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Carvedilol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Carvedilol.Approved
MethotrimeprazineThe metabolism of Carvedilol can be decreased when combined with Methotrimeprazine.Approved
MethoxamineCarvedilol may decrease the vasoconstricting activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Carvedilol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Carvedilol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carvedilol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carvedilol.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
MetyrosineCarvedilol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Carvedilol can be decreased when combined with Mexiletine.Approved
MibefradilCarvedilol may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Carvedilol.Approved, Illicit
MidodrineCarvedilol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Carvedilol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Carvedilol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Carvedilol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carvedilol.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Carvedilol.Approved
MitotaneThe serum concentration of Carvedilol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Carvedilol.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Carvedilol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Carvedilol.Approved
ModafinilThe serum concentration of Carvedilol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Carvedilol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Carvedilol.Approved
MoricizineMoricizine may increase the hypotensive activities of Carvedilol.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Carvedilol.Approved, Investigational
MoxonidineCarvedilol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Carvedilol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Carvedilol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Carvedilol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Carvedilol.Investigational
NafcillinThe serum concentration of Carvedilol can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the antihypertensive activities of Carvedilol.Approved
NaftopidilCarvedilol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Carvedilol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Carvedilol.Approved, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Carvedilol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Carvedilol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Carvedilol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Carvedilol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Carvedilol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Carvedilol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Carvedilol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Carvedilol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Carvedilol.Approved
NicorandilNicorandil may increase the hypotensive activities of Carvedilol.Approved
NicotineThe metabolism of Carvedilol can be decreased when combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Carvedilol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Carvedilol.Approved
NiguldipineCarvedilol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Carvedilol can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineCarvedilol may increase the hypotensive activities of Niludipine.Experimental
NilvadipineCarvedilol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideCarvedilol may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carvedilol.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Carvedilol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carvedilol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Carvedilol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Carvedilol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carvedilol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carvedilol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Carvedilol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
NylidrinCarvedilol may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabCarvedilol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Carvedilol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Carvedilol.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Carvedilol.Approved, Investigational
OlaparibThe metabolism of Carvedilol can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carvedilol.Approved, Investigational
OlodaterolCarvedilol may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Carvedilol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Carvedilol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Carvedilol.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Carvedilol.Approved
OmeprazoleThe serum concentration of Carvedilol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineCarvedilol may decrease the vasoconstricting activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Carvedilol.Vet Approved
OsimertinibThe serum concentration of Carvedilol can be increased when it is combined with Osimertinib.Approved
OuabainCarvedilol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Carvedilol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Carvedilol.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Carvedilol.Approved, Vet Approved
PalbociclibThe serum concentration of Carvedilol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
PanobinostatThe serum concentration of Carvedilol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Carvedilol.Approved
PargylinePargyline may increase the hypotensive activities of Carvedilol.Approved
ParoxetineThe metabolism of Carvedilol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideCarvedilol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Carvedilol.Approved
Peginterferon alfa-2bThe serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
PentobarbitalThe metabolism of Carvedilol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Carvedilol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Carvedilol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Carvedilol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved, Withdrawn
PerhexilineCarvedilol may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Carvedilol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Carvedilol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Carvedilol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Carvedilol.Withdrawn
PhenobarbitalThe metabolism of Carvedilol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Carvedilol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Carvedilol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Carvedilol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
PhenylephrineCarvedilol may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Carvedilol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Carvedilol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
PinacidilCarvedilol may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumCarvedilol may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Pipamperone.Approved
PirbuterolCarvedilol may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Carvedilol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Carvedilol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Carvedilol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Carvedilol.Withdrawn
PolythiazideCarvedilol may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Carvedilol.Approved
Poractant alfaCarvedilol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Carvedilol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Carvedilol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Carvedilol.Approved
PrazosinPrazosin may increase the antihypertensive activities of Carvedilol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Carvedilol.Approved, Vet Approved
PregabalinCarvedilol may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineCarvedilol may increase the hypotensive activities of Prenylamine.Withdrawn
PrimaquineThe metabolism of Carvedilol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Carvedilol can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolCarvedilol may decrease the vasoconstricting activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Carvedilol.Approved, Vet Approved
PromazineThe metabolism of Carvedilol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Carvedilol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Carvedilol.Approved
PropafenoneThe serum concentration of Carvedilol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Carvedilol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Carvedilol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Carvedilol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Carvedilol.Approved
PyrimethamineThe serum concentration of Carvedilol can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Carvedilol.Approved, Investigational
QuinidineThe metabolism of Carvedilol can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Carvedilol can be increased when it is combined with Quinine.Approved
RacepinephrineCarvedilol may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineCarvedilol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carvedilol.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Carvedilol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Carvedilol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Carvedilol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Carvedilol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Carvedilol.Approved
RescinnamineCarvedilol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Carvedilol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Carvedilol.Experimental, Investigational
RifabutinThe metabolism of Carvedilol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Carvedilol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Carvedilol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Carvedilol.Approved, Investigational
RilmenidineCarvedilol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Carvedilol is combined with Riociguat.Approved
RisedronateCarvedilol may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneCarvedilol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronCarvedilol may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineCarvedilol may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe metabolism of Carvedilol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCarvedilol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Carvedilol.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Carvedilol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Carvedilol.Investigational, Withdrawn
RolapitantThe metabolism of Carvedilol can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Carvedilol.Approved, Investigational
RomifidineCarvedilol may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Carvedilol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Carvedilol.Withdrawn
SalbutamolCarvedilol may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Carvedilol.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Carvedilol.Approved, Vet Approved
SalmeterolCarvedilol may decrease the vasoconstricting activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Carvedilol.Approved
SaprisartanCarvedilol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Carvedilol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Carvedilol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Carvedilol.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Carvedilol.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
SertralineThe metabolism of Carvedilol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Carvedilol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Carvedilol can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.Approved
SiltuximabThe serum concentration of Carvedilol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Carvedilol can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Carvedilol.Approved, Investigational
SitaxentanCarvedilol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Carvedilol is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Carvedilol.Approved
SolabegronCarvedilol may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Carvedilol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Carvedilol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Carvedilol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Carvedilol.Experimental
SpiraprilCarvedilol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carvedilol.Approved
SR 58611Carvedilol may decrease the vasoconstricting activities of SR 58611.Investigational
SRT501SRT501 may decrease the antihypertensive activities of Carvedilol.Investigational
St. John's WortThe serum concentration of Carvedilol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Carvedilol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Carvedilol is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Carvedilol.Approved, Investigational
SulfadiazineThe serum concentration of Carvedilol can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Carvedilol can be increased when it is combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Carvedilol.Approved
SulfisoxazoleThe serum concentration of Carvedilol can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Carvedilol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Withdrawn
SynephrineCarvedilol may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Carvedilol.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Carvedilol.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Carvedilol.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Carvedilol.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Carvedilol.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Carvedilol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Carvedilol.Approved
TelaprevirThe metabolism of Carvedilol can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Carvedilol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carvedilol.Approved, Investigational
TemocaprilCarvedilol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Carvedilol.Approved
TenofovirThe metabolism of Carvedilol can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Carvedilol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Carvedilol.Vet Approved
TerazosinCarvedilol may increase the antihypertensive activities of Terazosin.Approved
TerbinafineThe metabolism of Carvedilol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineCarvedilol may decrease the vasoconstricting activities of Terbutaline.Approved
TeriflunomideThe serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.Approved
TerlipressinCarvedilol may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Carvedilol can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Carvedilol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ThioridazineThe metabolism of Carvedilol can be decreased when combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Carvedilol.Approved
TiboloneCarvedilol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Carvedilol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Carvedilol can be increased when it is combined with Ticlopidine.Approved
TicrynafenCarvedilol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Carvedilol.Investigational
TipranavirThe metabolism of Carvedilol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
TocilizumabThe serum concentration of Carvedilol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Carvedilol.Approved, Investigational
TolazamideCarvedilol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TolbutamideThe serum concentration of Carvedilol can be increased when it is combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Carvedilol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidCarvedilol may increase the hypotensive activities of Tolfenamic Acid.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Carvedilol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Carvedilol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Carvedilol.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Carvedilol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Carvedilol.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Carvedilol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carvedilol.Approved
TranilastCarvedilol may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carvedilol.Experimental
TranylcypromineThe metabolism of Carvedilol can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Carvedilol.Approved
TravoprostTravoprost may increase the hypotensive activities of Carvedilol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Carvedilol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Carvedilol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Carvedilol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Carvedilol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TrimazosinCarvedilol may increase the antihypertensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Carvedilol.Approved
TrimethoprimThe serum concentration of Carvedilol can be increased when it is combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Carvedilol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Carvedilol.Approved
TulobuterolCarvedilol may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Carvedilol.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Carvedilol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Carvedilol.Approved
UnoprostoneCarvedilol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Carvedilol.Investigational, Withdrawn
Valproic AcidThe serum concentration of Carvedilol can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe serum concentration of Carvedilol can be increased when it is combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Carvedilol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Carvedilol.Approved
VemurafenibThe serum concentration of Carvedilol can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Carvedilol.Approved
VenlafaxineThe metabolism of Carvedilol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Carvedilol.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Carvedilol.Approved, Investigational
VinpocetineCarvedilol may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Carvedilol.Approved
VoriconazoleThe serum concentration of Carvedilol can be increased when it is combined with Voriconazole.Approved, Investigational
XylazineCarvedilol may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
YM-178Carvedilol may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
ZafirlukastThe serum concentration of Carvedilol can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Carvedilol.Approved
ZiconotideCarvedilol may increase the hypotensive activities of Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Carvedilol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Carvedilol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Carvedilol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Carvedilol can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Carvedilol.Withdrawn
Food Interactions
  • Take with food, food slows the absorption rate and reduces the incidence of adverse effects (extent of absorption is not affected).
References
Synthesis Reference

Ilan Kor, “Crystalline solids of carvedilol and processes for their preparation.” U.S. Patent US20030166702, issued September 04, 2003.

US20030166702
General References
  1. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9. [PubMed:12390947 ]
  2. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. [PubMed:11386263 ]
  3. Vanderhoff BT, Ruppel HM, Amsterdam PB: Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998 Nov 1;58(7):1627-34, 1641-2. [PubMed:9824960 ]
External Links
ATC CodesC07AG02
AHFS Codes
  • 24:04.00
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (1.25 MB)
MSDSDownload (32.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9706
Blood Brain Barrier-0.6814
Caco-2 permeable-0.6308
P-glycoprotein substrateSubstrate0.8552
P-glycoprotein inhibitor INon-inhibitor0.8729
P-glycoprotein inhibitor IINon-inhibitor0.6521
Renal organic cation transporterNon-inhibitor0.5405
CYP450 2C9 substrateNon-substrate0.7517
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5408
CYP450 1A2 substrateInhibitor0.524
CYP450 2C9 inhibitorNon-inhibitor0.8496
CYP450 2D6 inhibitorNon-inhibitor0.7274
CYP450 2C19 inhibitorNon-inhibitor0.5676
CYP450 3A4 inhibitorNon-inhibitor0.6352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6048
Ames testNon AMES toxic0.8261
CarcinogenicityNon-carcinogens0.9692
BiodegradationNot ready biodegradable0.963
Rat acute toxicity2.4566 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5725
hERG inhibition (predictor II)Inhibitor0.8889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral12.5 mg/1
TabletOral25 mg/1
TabletOral25.0 mg
TabletOral3.125 mg/1
TabletOral6.25 mg/1
Tablet, film coatedOral12.5 mg/1
Tablet, film coatedOral12.5 mg/301
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral3.125 mg/1
Tablet, film coatedOral6.25 mg/1
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral80 mg/1
TabletOral50 mg
Kit
TabletOral12.5 mg
TabletOral25 mg
TabletOral3.125 mg
TabletOral6.25 mg
Prices
Unit descriptionCostUnit
Coreg CR 10 mg 24 Hour Capsule4.77USD capsule
Coreg CR 20 mg 24 Hour Capsule4.77USD capsule
Coreg CR 40 mg 24 Hour Capsule4.77USD capsule
Coreg CR 80 mg 24 Hour Capsule4.77USD capsule
Coreg cr 10 mg capsule4.59USD capsule
Coreg cr 20 mg capsule4.59USD capsule
Coreg cr 40 mg capsule4.59USD capsule
Coreg cr 80 mg capsule4.59USD capsule
Coreg 12.5 mg tablet2.54USD tablet
Coreg 25 mg tablet2.54USD tablet
Coreg 3.125 mg tablet2.54USD tablet
Coreg 6.25 mg tablet2.54USD tablet
Carvedilol 12.5 mg tablet2.18USD tablet
Carvedilol 25 mg tablet2.18USD tablet
Carvedilol 3.125 mg tablet2.18USD tablet
Carvedilol 6.25 mg tablet2.18USD tablet
Apo-Carvedilol 12.5 mg Tablet0.84USD tablet
Apo-Carvedilol 25 mg Tablet0.84USD tablet
Apo-Carvedilol 3.125 mg Tablet0.84USD tablet
Apo-Carvedilol 6.25 mg Tablet0.84USD tablet
Phl-Carvedilol 12.5 mg Tablet0.79USD tablet
Phl-Carvedilol 3.125 mg Tablet0.79USD tablet
Phl-Carvedilol 6.25 mg Tablet0.79USD tablet
Pms-Carvedilol 12.5 mg Tablet0.79USD tablet
Pms-Carvedilol 25 mg Tablet0.79USD tablet
Pms-Carvedilol 3.125 mg Tablet0.79USD tablet
Pms-Carvedilol 6.25 mg Tablet0.79USD tablet
Ran-Carvedilol 12.5 mg Tablet0.79USD tablet
Ran-Carvedilol 25 mg Tablet0.79USD tablet
Ran-Carvedilol 3.125 mg Tablet0.79USD tablet
Ran-Carvedilol 6.25 mg Tablet0.79USD tablet
Ratio-Carvedilol 12.5 mg Tablet0.79USD tablet
Ratio-Carvedilol 25 mg Tablet0.79USD tablet
Ratio-Carvedilol 3.125 mg Tablet0.79USD tablet
Ratio-Carvedilol 6.25 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6022562 Yes1996-04-172016-04-17Us
US7268156 Yes2003-12-272023-12-27Us
US8101209 Yes2006-03-112026-03-11Us
USRE40000 Yes1995-12-072015-12-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114.5 °CPhysProp
water solubilityPractically insoluble (0.583 mg/L)Not Available
logP4.19AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00444 mg/mLALOGPS
logP3.05ALOGPS
logP3.42ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)8.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area75.74 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.64 m3·mol-1ChemAxon
Polarizability45.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents
Substituents
  • Carbazole
  • Indole
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Pyrrole
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. [PubMed:1712335 ]
  2. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 1989;39(5):327-36. [PubMed:2575762 ]
  3. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989;1(4):265-70. [PubMed:2577144 ]
  4. de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D, Belz GG: Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther. 1994 Mar;55(3):329-37. [PubMed:7908256 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.
Gene Name:
NDUFC2
Uniprot ID:
O95298
Molecular Weight:
14187.33 Da
References
  1. Oliveira PJ, Santos DJ, Moreno AJ: Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch Biochem Biophys. 2000 Feb 15;374(2):279-85. [PubMed:10666308 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Irodova NL, Krasnikova TL, Masenko VP, Kochetov AG, Chazova IE: [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors]. Ter Arkh. 2002;74(8):30-4. [PubMed:12360591 ]
  2. Maebara C, Ohtani H, Sugahara H, Mine K, Kubo C, Sawada Y: Nightmares and panic disorder associated with carvedilol overdose. Ann Pharmacother. 2002 Nov;36(11):1736-40. [PubMed:12398570 ]
  3. Okajima K, Harada N, Uchiba M, Isobe H: Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats. J Pharmacol Exp Ther. 2004 May;309(2):684-91. Epub 2004 Feb 5. [PubMed:14764656 ]
  4. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. [PubMed:1712335 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Vascular endothelial growth factor receptor binding
Specific Function:
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activ...
Gene Name:
VEGFA
Uniprot ID:
P15692
Molecular Weight:
27042.205 Da
References
  1. de Boer RA, Siebelink HJ, Tio RA, Boomsma F, van Veldhuisen DJ: Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail. 2001 Jun;3(3):331-3. [PubMed:11378004 ]
  2. Saijonmaa O, Nyman T, Fyhrquist F: Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol. 2004 May;43(5):616-21. [PubMed:15071347 ]
  3. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. [PubMed:15732037 ]
  4. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H: Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-20. [PubMed:15942707 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Receptor binding
Specific Function:
Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3.
Gene Name:
NPPB
Uniprot ID:
P16860
Molecular Weight:
14725.825 Da
References
  1. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol. 2000;36 Suppl 2:S19-23. [PubMed:11206715 ]
  2. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001 Jun 1;37(7):1781-7. [PubMed:11401111 ]
  3. Konishi H, Nishio S, Tsutamoto T, Minouchi T, Yamaji A: Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. Int J Clin Pharmacol Ther. 2003 Dec;41(12):578-86. [PubMed:14692707 ]
  4. Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M: Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004 Aug 15;94(4):448-53. [PubMed:15325927 ]
  5. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC: Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005 Mar;149(3):541-7. [PubMed:15864245 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Signal transducer activity
Specific Function:
Gap junction protein that acts as a regulator of bladder capacity. A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a critical role in the physiology of hearing by participating in the recycling of potassium to the cochlear endolymph. Negative regulator o...
Gene Name:
GJA1
Uniprot ID:
P17302
Molecular Weight:
43008.005 Da
References
  1. Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH: Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. [PubMed:16448880 ]
  2. Fan SY, Ke YN, Zeng YJ, Wang Y, Cheng WL, Yang JR: [Effects and the mechanism of carvedilol on gap junctional intercellular communication in rat myocardium]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1141-5. [PubMed:16563290 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, Kiehn J: Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001 Feb 1;49(2):361-70. [PubMed:11164846 ]
  2. Kawakami K, Nagatomo T, Abe H, Kikuchi K, Takemasa H, Anson BD, Delisle BP, January CT, Nakashima Y: Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. [PubMed:16314852 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation.
Gene Name:
VCAM1
Uniprot ID:
P19320
Molecular Weight:
81275.43 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. [PubMed:15374848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222 ]
  2. Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA: Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20. [PubMed:18657662 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane signaling receptor activity
Specific Function:
Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with PSGL1/SELPLG. May have a role in capillary morphogenesis.
Gene Name:
SELE
Uniprot ID:
P16581
Molecular Weight:
66654.575 Da
References
  1. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. [PubMed:15374848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
modulator
General Function:
Ubiquitin protein ligase binding
Specific Function:
Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essentia...
Gene Name:
HIF1A
Uniprot ID:
Q16665
Molecular Weight:
92669.595 Da
References
  1. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. [PubMed:15732037 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular Weight:
146422.99 Da
References
  1. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ: Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 1994 Mar;28(3):400-6. [PubMed:7909721 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  3. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255 ]
  4. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H: Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79. [PubMed:10783826 ]
  5. Hokama N, Hobara N, Sakai M, Kameya H, Ohshiro S, Sakanashi M: Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol. 2002 Jun;54(6):821-5. [PubMed:12078998 ]
  6. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K: Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003 Jan;94(1):81-6. [PubMed:12708479 ]
  7. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58